Dialysis Drug Linked to Chronic Colitis Case
A case report details how sevelamer crystals caused severe intestinal irritation in a dialysis patient.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Would you stop taking a prescribed medication if you experienced new, concerning side effects?
Medical professionals identified sevelamer carbonate as the cause of a 56-year-old dialysis patient’s persistent gastrointestinal distress. Published on September 14, 2026, the case highlights risks for those managing high phosphorus levels through medication.
Why it matters
The findings underscore the importance of monitoring for potential side effects when using phosphate binders to manage high phosphorus levels in kidney care. Recognizing these symptoms early can lead to effective treatment adjustments and rapid recovery.
A case report published September 14, 2026, documented a 56-year-old patient who developed colitis after taking 800 mg of sevelamer four times daily for three months. Biopsies confirmed the presence of crystalline material consistent with the drug in the patient's colon ulcers.
The players
Renvela
A brand-name phosphate binder medication that carries warnings for potential complications including colitis and intestinal necrosis.
The details
Sevelamer carbonate is a phosphate binder designed to remain in the digestive tract to prevent phosphorus absorption. In this instance, the medication accumulated and formed crystals that caused localized tissue irritation and inflammation. Doctors identified these distinct fish-scale crystals during a biopsy, which triggered the symptoms of abdominal pain, vomiting, and diarrhea.
Timeline
2013: Pathologists first described the features of sevelamer crystals in medical literature.
September 14, 2026: The case report was published in Oxford Medical Case Reports.
Health Landscape
This case report provides real-world clinical evidence that reinforces existing safety warnings found in the FDA-approved prescribing label for Renvela. It highlights the rare but significant gastrointestinal risks associated with long-term phosphate binder use in dialysis patients.
If you are currently taking a phosphate binder and experience persistent abdominal pain or diarrhea, contact your healthcare provider to discuss your symptoms. Always speak with your doctor before making any changes to your prescribed medication regimen.
The takeaway
Medications used to manage phosphorus levels can occasionally cause unexpected gastrointestinal side effects. If you are experiencing digestive discomfort, share your current list of medications with your physician to determine if an adjustment is appropriate.
Further reading
Learn more about managing kidney health complications in our Diabetes section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Would you stop taking a prescribed medication if you experienced new, concerning side effects?
